Judicial attention to inflated pricing on drugs and medical equipment has drawn hospitals into the conversation, raising questions about how the broader healthcare industry might absorb any resulting financial adjustments.

During the 4 October session, bench members raised the question of why price-cap measures had been drawn narrowly around non-scheduled anti-cancer drugs, pressing the government to outline what actions it intended to pursue against excessive pricing across the broader medicines market.

Ashwin Sapra, a partner at Trilegal focusing on corporate, pharmaceutical, healthcare, and life sciences matters, noted that any move toward broader price controls would need to account for the full supply chain — from manufacturers and importers through to distributors, retailers, hospitals, and patients — adding that applying pressure at a single point along that chain was unlikely to bring overall prices down. Sapra also noted that tighter controls on pricing carry the potential to undermine the business case for launching new pharmaceuticals and medical devices in the Indian market, and that when pharmaceutical returns fall short of what investment demands, access to newer therapies may narrow.

Expanded trade margin caps — if policymakers move to broaden their application under external pressure — would carry financial consequences for both hospital operators and pharmaceutical manufacturers. Broadening trade margin caps to cover additional medicines and consumables represents a potential headwind for hospital revenues, in the view of Macquarie Capital pharma and healthcare analyst Kunal Dhamesha.

According to Dhamesha's figures, pharmacy operations bring in roughly a fifth to a quarter of total hospital revenue. Analysts estimate that narrowing the assumed trade markup from 50% down to 30% would pull revenue back by roughly 4% to 5%, with a corresponding reduction likely feeding through into EBITDA. A portion of hospital EBITDA in the high-teens percentage range stood to be affected, according to his assessment. That figure, he noted, rests on a blanket 50% markup assumption, meaning the real-world effect will vary depending on the profit margins tied to specific products and how broadly any eventual policy is drawn.

Proposed caps on what hospitals may bill for supplies and consumables could put pressure on their operating margins, industry figures indicate. One avenue open to hospitals involves recalibrating fees on other parts of their service portfolio to absorb some of the strain, though what those providers can actually deliver may shift based on the composition of the patients they serve.

Dhamesha noted that patients settling bills directly in cash make up somewhere between 35 and 40 per cent of total revenue at listed private hospitals. For uninsured patients, pricing adjustments tend to be more straightforward for hospitals to implement, whereas those covered under insurance plans face a different dynamic — contracted rate structures leave providers with considerably less room to manoeuvre.

On 27 October, the Supreme Court is set to hear a case with direct consequences for both drug makers and hospital groups. Where drug pricing policy stands, how broadly trade margin caps extend, and what rules apply to medical consumables may all become clearer once a decision is reached.

Sapra contended that balancing what patients can realistically afford against the financial sustainability of the broader healthcare system ought to sit at the heart of any workable policy, and that authorities would need to bring relevant parties to the table for consultation ahead of any decisions being locked in on drug pricing and supply.